Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of LYTIX BIOPHARMA NK -,10
No Price
Closing Price XOSL 28.04.2026:
10,30 NOK
28.04.2026 13:59
Current Prices from LYTIX BIOPHARMA NK -,10
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
OSLO BORS
LYTIX.OL
NOK
28.04.2026 13:59
10,30 NOK
0,00 NOK
Share Float & Liquidity
Free Float99,74 %
Shares Float62,67 M
Shares Outstanding62,83 M
Company Profile for LYTIX BIOPHARMA NK -,10 Share
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
